U.S. markets closed
  • S&P Futures

    4,695.25
    -3.75 (-0.08%)
     
  • Dow Futures

    35,718.00
    -28.00 (-0.08%)
     
  • Nasdaq Futures

    16,380.00
    -12.25 (-0.07%)
     
  • Russell 2000 Futures

    2,265.80
    -4.00 (-0.18%)
     
  • Crude Oil

    72.57
    +0.21 (+0.29%)
     
  • Gold

    1,785.20
    -0.30 (-0.02%)
     
  • Silver

    22.45
    +0.02 (+0.10%)
     
  • EUR/USD

    1.1343
    -0.0001 (-0.01%)
     
  • 10-Yr Bond

    1.5090
    +0.0290 (+1.96%)
     
  • Vix

    19.90
    -1.99 (-9.09%)
     
  • GBP/USD

    1.3201
    -0.0005 (-0.04%)
     
  • USD/JPY

    113.7880
    +0.0510 (+0.04%)
     
  • BTC-USD

    50,473.54
    -267.08 (-0.53%)
     
  • CMC Crypto 200

    1,321.33
    +16.22 (+1.24%)
     
  • FTSE 100

    7,337.05
    -2.85 (-0.04%)
     
  • Nikkei 225

    28,869.02
    +8.40 (+0.03%)
     

Bronstein, Gewirtz & Grossman, LLC Alerts of Class Action Against iRobot Corporation (IRBT), Zendesk, Inc. (ZEN) & Zynerba Pharmaceuticals, Inc. (ZYNE)

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, NY / ACCESSWIRE / November 22, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

iRobot Corporation (NASDAQ:IRBT)

Class Period: November 21, 2016 - October 22, 2019

Deadline: December 23, 2019
For more info: www.bgandg.com/irbt

The Complaint alleges that, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) iRobot's explosive growth was not based on increased demand, expanding margins, and product innovations, as it claimed, but rather based on channel stuffing; (2) the Company attempted to conceal its actions by acquiring its distributors in Europe and Asia; (3) these acquisitions were designed to clean up the company's global inventory and mask falling demand; and (4) as a result, iRobot's public statements were materially false and misleading at all relevant times.

Zendesk, Inc. (ZEN)

Class Period: February 6, 2019 - October 1, 2019

Deadline: December 23, 2019
For more info: www.bgandg.com/zen

The Complaint alleges that, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Zendesk's clients had been subject to data breaches dating back to 2016; (2) Zendesk was experiencing slowing demand for its SaaS offerings, particularly in Germany, the U.K. and Australia, due in large part to political uncertainty and China trade issues; (3) for the forgoing reasons, Zendesk's business metrics and financial prospects were not as strong as represented during the Class Period; and (4) as a result, Zendesk's public statements were materially false and misleading at all relevant times.

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE)

Class Period: March 11, 2019 - September 17, 2019

Deadline: December 23, 2019
For more info: www.bgandg.com/zyne

The Complaint alleges that, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Zygel was proving unsafe and not well-tolerated in the BELIEVE 1 Trial; (2) the foregoing created a foreseeable, heightened risk that Zynerba would fail to secure the necessary regulatory approvals for commercializing Zygel for the treatment of DEE in children and adolescents; and (3) as a result, the Company's public statements were materially false and misleading at all relevant times.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC



View source version on accesswire.com:
https://www.accesswire.com/566963/Bronstein-Gewirtz-Grossman-LLC-Alerts-of-Class-Action-Against-iRobot-Corporation-IRBT-Zendesk-Inc-ZEN-Zynerba-Pharmaceuticals-Inc-ZYNE